规格: | 5mg | 产品价格: | 740 |
---|
规格: | 10mg | 产品价格: | 1100 |
---|
规格: | 50mg | 产品价格: | 3040 |
---|
规格: | 100mg | 产品价格: | 5240 |
---|
Catalog Number GC10355
Molecular Formula C21H19N3O5
Relative Molecular Mass 393.39
CAS Registry Number 1194506-26-7
Formulation A solid
Purity ≥98%
Storage Store at -20°C
SMILES CC(O1)=C(/C(O)=N/C)C2=C1C=C(OC3=NC=NC4=CC(OC)=C(OC)C=C43)C=C2
产品描述
IC50: 33 nmol/L, 35 nmol/L and 0.5 nmol/L for VEGFR1, 2, 3VEGF/VEGFR signal has been proven to be an important target for development of novel cancer therapies. One challenging aspect in VEGFR inhibitors is to achieve sustained target inhibition at tolerable doses previously seen only with the long-acting biologics. Fruquintinib is a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.In vitro: Fruquintinib was found to inhibit VEGFR2 with an IC50 of 25 nmol/L. The kinase selectivity of fruquintinib was evaluated against a panel of 253 kinases. The results showed that fruquintinib inhibited VEGFR family members with weak inhibition of RET, FGFR-1 and c-kit kinases [1]. In vivo: Anti-tumor activity of fruquintinib was evaluated in a variety of tumor xenografts. The results from gastric cancer BGC-823 model seemed to indicate that the drug concentration needs to be at least maintained above EC85 for around 8 hours in order to achieve >80% tumor growth inhibition. BGC-823 was found to be most sensitive to fruquintinib [1]. Clinical trial: Fruquintinib (HMPL-013) is currently in Phase II clinical studies. Analysis of Phase I pharmacokinetic data revealed that at the maximum tolerated dose of once daily oral administration fruquintinib achieved complete VEGFR2 suppression for 24 hours/day [1].Reference:[1] Sun Q, Zhou J, Zhang Z, Guo M, Liang J, Zhou F, Long J, Zhang W, Yin F, Cai H, Yang H, Zhang W, Gu Y, Ni L, Sai Y, Cui Y, Zhang M, Hong M, Sun J, Yang Z, Qing W, Su W, Ren Y. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.
更多产品信息,请点击:https://www.glpbio.cn/search.php?catalog=GC10355原装进口,Fruquintinib(HMPL-013),美国GlpBio品Pai大包装更优惠!
美国Glpbio是一家领先的小分子YZ剂、激活剂、化合物库、多肽和实验室试剂的供应商。公司经营范围广泛,产品涉及癌症、免疫学、神经科学、细胞凋亡、表观遗传学等20多个不同研究领域,拥有10000多种产品。总部位于美国加利福尼亚,营销网点遍及法国、德国、加拿大、日本、澳大利亚、新加坡、以色列等20多个国家地区,竭诚为各国的科研工作者提供优质的产品和专业的服务。


温馨提示:不可用于临床ZL。